Pik Fang Kho1,2, Jonathan Fawcett2, Lin Fritschi3, Harvey Risch4, Penelope M Webb1,5, David C Whiteman1,5, Rachel E Neale6,7. 1. Population Health Department, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia. 2. School of Medicine, University of Queensland, Brisbane, Australia. 3. School of Public Health, Curtin University, Perth, Australia. 4. School of Public Health, Yale University, New Haven, CT, USA. 5. School of Public Health, University of Queensland, Brisbane, Australia. 6. Population Health Department, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia. Rachel.Neale@qimrberghofer.edu.au. 7. School of Public Health, University of Queensland, Brisbane, Australia. Rachel.Neale@qimrberghofer.edu.au.
Abstract
PURPOSE: Studies suggest that aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and statins may reduce risk of some cancers. However, findings have been conflicting as to whether these agents reduce the risk of pancreatic cancer. METHODS: We used data from the Queensland Pancreatic Cancer Study, a population-based case-control study. In total, 704 cases and 711 age- and sex-matched controls were recruited. Participants completed an interview in which they were asked about history of NSAID and statin use. We included 522 cases and 653 controls who had completed the medication section of the interview in this analysis. Unconditional multivariable logistic regression was used to estimate associations between medication use and pancreatic cancer. RESULTS: We found no consistent evidence of an association between use of NSAIDs or statins and risk of pancreatic cancer. There was some suggestion of a protective effect in infrequent users of selective COX-2 inhibitors, but no association in more frequent users. We did not find evidence of protective effects in analyses stratified by sex, smoking status, time between diagnosis and interview, or presence/absence of metastases. CONCLUSIONS: Overall, our results do support the hypothesis that use of NSAIDs or statins may reduce the odds of developing pancreatic cancer.
PURPOSE: Studies suggest that aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and statins may reduce risk of some cancers. However, findings have been conflicting as to whether these agents reduce the risk of pancreatic cancer. METHODS: We used data from the Queensland Pancreatic Cancer Study, a population-based case-control study. In total, 704 cases and 711 age- and sex-matched controls were recruited. Participants completed an interview in which they were asked about history of NSAID and statin use. We included 522 cases and 653 controls who had completed the medication section of the interview in this analysis. Unconditional multivariable logistic regression was used to estimate associations between medication use and pancreatic cancer. RESULTS: We found no consistent evidence of an association between use of NSAIDs or statins and risk of pancreatic cancer. There was some suggestion of a protective effect in infrequent users of selective COX-2 inhibitors, but no association in more frequent users. We did not find evidence of protective effects in analyses stratified by sex, smoking status, time between diagnosis and interview, or presence/absence of metastases. CONCLUSIONS: Overall, our results do support the hypothesis that use of NSAIDs or statins may reduce the odds of developing pancreatic cancer.
Authors: Natalia Khalaf; Chen Yuan; Tsuyoshi Hamada; Yin Cao; Ana Babic; Vicente Morales-Oyarvide; Peter Kraft; Kimmie Ng; Edward Giovannucci; Shuji Ogino; Meir Stampfer; Barbara B Cochrane; JoAnn E Manson; Clary B Clish; Andrew T Chan; Charles S Fuchs; Brian M Wolpin Journal: Gastroenterology Date: 2017-12-08 Impact factor: 22.682